pretomanid + moxifloxacin + pyrazinamide

PaMZ is an experimental three-drug combination regimen for the treatment of tuberculosis (TB), consisting of pretomanid (P), moxifloxacin (M), and pyrazinamide (Z). Developed by the TB Alliance, the regimen is designed to shorten the treatment duration for both drug-sensitive and certain drug-resistant forms of TB. Pretomanid is a nitroimidazole that inhibits mycolic acid biosynthesis and induces respiratory poisoning in anaerobic bacteria. Moxifloxacin is a fluoroquinolone that targets bacterial DNA gyrase and topoisomerase IV, while pyrazinamide is a prodrug that disrupts mycobacterial membrane potential and transport. In specialized clinical contexts, such as spinal tuberculosis, PaMZ is being evaluated as part of a localized, controlled-release delivery system (e.g., thermosensitive gel microspheres) often combined with Bone Morphogenetic Protein-2 (BMP-2) to simultaneously treat the infection and promote bone healing.

Other names

PA-824 + moxifloxacin + pyrazinamide